A Study to Determine if Levetiracetam Will Assist Those Suffering From Chronic Idiopathic Axonal Polyneuropathy.
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
Considering the mechanisms of action which provide efficacy in epilepsy, it is hypothesized
that treatment with levetiracetam will reduce the neuronal excitability involved in
neuropathic pain associated with CIAP. Thus, there is a potential for levetiracetam to bring
therapeutic benefit for the subjects because of its specific mechanism of action, its safety
profile and the absence of interaction with other drugs.
Phase:
Phase 2
Details
Lead Sponsor:
Vanderbilt University Vanderbilt University Medical Center